EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)

Steven E Nissen, Helle Linnebjerg, Xi Shen, Kathy Wolski, Xiaosu Ma, Shufen Lim, Laura F Michael, Giacomo Ruotolo, Grace Gribble, Ann Marie Navar, Stephen J Nicholls

JAMA · 05.12.2023 · 330 (21) · 2075

DOI: 10.1001/jama.2023.21835 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift JAMA, erschienen am 05.12.2023. Verfasst von Steven E Nissen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Center for Clinical Research, Cleveland, Ohio. Hauptthemen laut MEDLINE: Lipoprotein(a), RNA, Small Interfering, Apolipoproteins A. Die Arbeit wurde bisher 239-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Epidemiological and genetic data have implicated lipoprotein(a) as a potentially modifiable risk factor for atherosclerotic disease and aortic stenosis, but there are no approved pharmacological treatments.

Objectives

To assess the safety, tolerability, pharmacokinetics, and effects of lepodisiran on lipoprotein(a) concentrations after single doses of the drug; lepodisiran is a short interfering RNA directed at hepatic synthesis of apolipoprotein(a), an essential component necessary for assembly of lipoprotein(a) particles. Design, Setting, and Participants A single ascending-dose trial conducted at 5 clinical research sites in the US and Singapore that enrolled 48 adults without cardiovascular disease and with lipoprotein(a) serum concentrations of 75 nmol/L or greater (or ≥30 mg/dL) between November 18, 2020, and December 7, 2021; the last follow-up visit occurred on November 9, 2022.

Interventions

Participants were randomized to receive placebo or a single dose of lepodisiran (4 mg, 12 mg, 32 mg, 96 mg, 304 mg, or 608 mg) administered subcutaneously. Main Outcomes and Measures The primary outcome was the safety and tolerability of the single ascending doses of lepodisiran. The secondary outcomes included plasma levels of lepodisiran for 168 days after dose administration and changes in fasting lipoprotein(a) serum concentrations through a maximum follow-up of 336 days (48 weeks).

Results

Of the 48 participants enrolled (mean age, 46.8 [SD, 11.6] years; 35% were women), 1 serious adverse event occurred. The plasma concentrations of lepodisiran reached peak levels within 10.5 hours and were undetectable by 48 hours. The median baseline lipoprotein(a) concentration was 111 nmol/L (IQR, 78 to 134 nmol/L) in the placebo group, 78 nmol/L (IQR, 50 to 152 nmol/L) in the 4 mg of lepodisiran group, 97 nmol/L (IQR, 86 to 107 nmol/L) in the 12-mg dose group, 120 nmol/L (IQR, 110 to 188 nmol/L) in the 32-mg dose group, 167 nmol/L (IQR, 124 to 189 nmol/L) in the 96-mg dose group, 96 nmol/L (IQR, 72 to 132 nmol/L) in the 304-mg dose group, and 130 nmol/L (IQR, 87 to 151 nmol/L) in the 608-mg dose group. The maximal median change in lipoprotein(a) concentration was −5% (IQR, −16% to 11%) in the placebo group, −41% (IQR, −47% to −20%) in the 4 mg of lepodisiran group, −59% (IQR, −66% to −53%) in the 12-mg dose group, −76% (IQR, −76% to −75%) in the 32-mg dose group, −90% (IQR, −94% to −85%) in the 96-mg dose group, −96% (IQR, −98% to −95%) in the 304-mg dose group, and −97% (IQR, −98% to −96%) in the 608-mg dose group. At day 337, the median change in lipoprotein(a) concentration was −94% (IQR, −94% to −85%) in the 608 mg of lepodisiran group. Conclusions and Relevance In this phase 1 study of 48 participants with elevated lipoprotein(a) levels, lepodisiran was well tolerated and produced dose-dependent, long-duration reductions in serum lipoprotein(a) concentrations. The findings support further study of lepodisiran. Trial Registration ClinicalTrials.gov Identifier: NCT04914546

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein(a)RNA, Small InterferingApolipoproteins AAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodRisk FactorsSingaporeLiverAdministration, CutaneousUnited States

Substanzen

Lipoprotein(a)RNA, Small InterferingApolipoproteins A

Autor:innen und Institutionen

  • Cleveland Clinic Center for Clinical Research, Cleveland, Ohio.
  • Eli Lilly and Company, Indianapolis, Indiana.
  • Department of Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas.
  • Victorian Heart Institute, Monash University, Clayton, Australia.

Zitieren

APA

Nissen, S. E., Linnebjerg, H., Shen, X., Wolski, K., Ma, X., Lim, S., Michael, L. F., Ruotolo, G., Gribble, G., Navar, A. M., & Nicholls, S. J. (2023). Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a). JAMA, 330(21), 2075. https://doi.org/10.1001/jama.2023.21835

Vancouver

Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a). JAMA. 2023;330(21):2075. doi:10.1001/jama.2023.21835

BibTeX
@article{Nissen2023,
  author = {Nissen, Steven E and Linnebjerg, Helle and Shen, Xi and Wolski, Kathy and Ma, Xiaosu and Lim, Shufen and Michael, Laura F and Ruotolo, Giacomo and Gribble, Grace and Navar, Ann Marie and Nicholls, Stephen J},
  title = {Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {21},
  pages = {2075},
  doi = {10.1001/jama.2023.21835}
}
Kostenlos starten →